• search
Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Pharmaceutical Microbiology Testing

Pharmaceutical Microbiology Testing

We offer pharmaceutical microbiology testing services with a wide range of in vitro assays and infectious models that can be tailored as per customer requirements.

The pharmaceutical microbiology testing service at Aurigene is supported by BSL-2 compliant lab and a dedicated in vivo facility for bacterial and fungal infection murine disease models. Our team has collaborated on numerous anti-bacterial and anti-fungal agent discovery projects with innovator pharma companies. We have a dedicated team of scientists and allied staff with vast experience in anti-infective drug discovery projects. We have established in vitro assays and in vivo murine efficacy models.

We also support generic product filings through bioequivalance studies of in vitro time-kill kinetics against reference drug.

Speak to our experts

In vitro Pharmaceutical Microbiology Testing Services

  • Pharmacodynamic studies:   Drug-organism interaction
  • MIC and MBC:   Susceptibility indicators; major parameters used to quantify the activity of an antibacterial agent against the target pathogen
  • Time kill kinetics:   Information on the time course and rate of antimicrobial activity
  • PAE and PA-SME:   Information on persistent effects of antibacterial agents
  • Others:   Antimicrobial combination/effect of serum proteins on MIC/ biofilm studies

In vivo Pharmaceutical Microbiology Testing Services

  • Systemic infection models:   Acute lethal model to generate POC and determine ED50 - primary screening
  • Respiratory tract infection models:   Test efficacy of NCEs in highly vascularized tissue like lungs
  • Thigh infection models:   Test efficacy of NCEs in poorly vascularized tissues like thighs
  • Urinary tract infection models:   Testability of NCEs to clear UTIs
  • Organ burden models:   Testability of NCEs to clear the disseminated infection

Why Aurigene Pharmaceutical Services?

Submissions to the US FDA

Highly qualified & experienced scientists

Audited by the US FDA with Zero 483 in 2019

BSL-2 compliant microbiology lab

Wide range of infectious models & microbiology assay capabilities

Virtual Tour

 

Contact Us

Country
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
resourceMainImage

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More
resourceMainImage

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More
resourceMainImage

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug

2023

Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack